RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. and ABLYNX N.V.Research Collaboration and Exclusive License Agreement • October 17th, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • New York
THIS RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), effective as of January 31, 2014 (the “Effective Date”), is made by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”) and ABLYNX N.V., a limited liability company organized and existing under the laws of Belgium (“Ablynx”) registered with the legal entities register under number BE 0475295446 (district of Ghent) and whose registered office is situated at Technologiepark 21, 9052 Zwijnaarde, Belgium.
AMENDMENTResearch Collaboration and Exclusive License Agreement • October 17th, 2017 • Ablynx NV • Biological products, (no disgnostic substances)
This amendment (”Amendment”), executed on July 20, 2015, is an amendment to the RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT with an effective date of January 31, 2014 (“Agreement”) entered into by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”) and ABLYNX N.V., a limited liability company organized and existing under the laws of Belgium (“Ablynx”) registered with the legal entities register under number BE 0475295446 (district of Ghent) and whose registered office is situated at Technologiepark 21, 9052 Zwijnaarde, Belgium.
ABLYNX NV (a public limited liability company (“naamloze vennootschap”) organized and existing under the laws of the Kingdom of Belgium) Ordinary Shares and American Depositary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • October 17th, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • New York
